Lilly USA Overview

  • Year Founded
  • 1876

Year Founded

  • Status
  • Public

  • Employees
  • 50,000

Employees

  • Stock Symbol
  • LLY

Stock Symbol

  • Investments
  • 249

  • Share Price
  • $1.35K
  • (As of Thursday Closing)

Lilly USA General Information

Description

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Contact Information

Website
www.lilly.com
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • Lilly Corporate Center
  • Indianapolis, IN 46285
  • United States
+1 (317)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
NYS
Corporate Office
  • Lilly Corporate Center
  • Indianapolis, IN 46285
  • United States
+1 (317)

Lilly USA Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Lilly USA Stock Performance

As of 19-Nov-2026, Lilly USA’s stock price is $1.35K. Its current market cap is $1.2T with 891M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.35K $1.38K $850.51 - $1.48K $1.2T 891M 2.58M $30.85

Lilly USA Financials Summary

As of 30-Sep-2026, Lilly USA has a trailing 12-month revenue of $86.5B.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 1,077,329,433 994,509,358 721,953,716 571,131,575
Revenue 86,462,000 65,179,000 45,043,000 34,124,000
EBITDA 37,998,000 27,728,000 14,447,000 8,081,000
Net Income 27,580,000 20,640,000 10,590,000 5,240,000
Total Assets 148,072,000 112,476,000 78,715,000 64,006,300
Total Debt 49,503,000 42,503,000 33,644,000 25,225,300
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Lilly USA Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Lilly USA‘s full profile, request access.

Request a free trial

Lilly USA Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products inc
Drug Discovery
Indianapolis, IN
50,000 As of 2025

Thousand Oaks, CA
 

Princeton, NJ
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Lilly USA Competitors (31)

One of Lilly USA’s 31 competitors is Amgen, a Formerly PE-Backed company based in Thousand Oaks, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Amgen Formerly PE-Backed Thousand Oaks, CA
Bristol-Myers Squibb Corporation Princeton, NJ
AbbVie Corporation North Chicago, IL
Pfizer Corporation New York, NY
Merck & Co. Corporation Rahway, NJ
You’re viewing 5 of 31 competitors. Get the full list »

Lilly USA Patents

Lilly USA Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2026906711-A0 Combination therapies for treating cancer Pending 31-Jul-2026
CA-246920-S Box Active 27-Jun-2025
WO-2026231470-A1 Injection device Pending 02-May-2025
WO-2026231928-A1 Bolus perfusion culture methods Pending 30-Apr-2025
WO-2026226900-A2 Methods for producing one arm antibody molecules and methods for producing engineered cysteine antibody conjugation Pending 25-Apr-2025 C07K16/00
To view Lilly USA’s complete patent history, request access »

Lilly USA Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Lilly USA Investments & Acquisitions (249)

Lilly USA’s most recent deal was a Merger/Acquisition with Calytrix Bio for . The deal was made on 16-Nov-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Calytrix Bio 16-Nov-2026 Merger/Acquisition Drug Discovery
SRTD Biotech 09-Nov-2026 Seed Round Drug Discovery
T-Therapeutics 05-Nov-2026 Early Stage VC Drug Discovery
BigHat Biosciences 24-Sep-2026 Later Stage VC Drug Discovery
AtaiBeckley 09-Sep-2026 Merger/Acquisition Biotechnology
You’re viewing 5 of 249 investments and acquisitions. Get the full list »

Lilly USA ESG

Risk Overview

Risk Rating

Updated November, 17, 2026

20.34 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 354

Rank

Percentile

To view Lilly USA’s complete esg history, request access »

Lilly USA Exits (60)

Lilly USA’s most recent exit was on 05-May-2026 from Cabaletta Bio. The exit was categorized as with 4 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
Cabaletta Bio 05-May-2026 Completed
  • 4 buyers
Sunbird Bio 16-Oct-2024 Completed
  • 6 buyers
Aktis Oncology 20-Sep-2024 Completed
  • 14 buyers
Elektrofi 08-Aug-2024 Completed
  • 20 buyers
Ionetix 07-Aug-2024 Later Stage VC Completed
  • 2 buyers
You’re viewing 5 of 60 exits. Get the full list »

Lilly USA Affiliates

Subsidiaries (17)

Name Industry Location Year Founded
Kelonia Boston, MA 2021
Centessa Pharmaceuticals Altrincham, United Kingdom 2019
Ajax Therapeutics New York, NY 2019
4E Therapeutics Austin, TX 2019
Verve Therapeutics Boston, MA 2018
You’re viewing 5 of 17 affiliates. Get the full list.  »

Lilly USA FAQs

  • When was Lilly USA founded?

    Lilly USA was founded in 1876.

  • Where is Lilly USA headquartered?

    Lilly USA is headquartered in Indianapolis, IN.

  • What is the size of Lilly USA?

    Lilly USA has 50,000 total employees.

  • What industry is Lilly USA in?

    Lilly USA’s primary industry is Drug Discovery.

  • Is Lilly USA a private or public company?

    Lilly USA is a Public company.

  • What is Lilly USA’s stock symbol?

    The ticker symbol for Lilly USA is LLY.

  • What is the current stock price of Lilly USA?

    As of 19-Nov-2026 the stock price of Lilly USA is $1.35K.

  • What is the current market cap of Lilly USA?

    The current market capitalization of Lilly USA is $1.2T.

  • What is Lilly USA’s current revenue?

    The trailing twelve month revenue for Lilly USA is $86.5B.

  • Who are Lilly USA’s competitors?

    Amgen, Bristol-Myers Squibb, AbbVie, Pfizer, and Merck & Co. are some of the 31 competitors of Lilly USA.

  • What is Lilly USA’s annual earnings per share (EPS)?

    Lilly USA’s EPS for 12 months was $30.85.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process